Tysabri vs Cimzia for Crohn's Disease: A Patient Guide

Tysabri and Cimzia are both less commonly prescribed biologics for moderate-to-severe Crohn's disease, each with specific niches in the treatment landscape. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic with a distinctive structure that makes it notable for pregnancy considerations. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk. This guide walks through the tysabri vs cimzia crohn's comparison.

Anti-TNF vs Integrin Mechanism

Cimzia binds TNF-alpha, reducing inflammation throughout the body and in the gut. Cimzia's unique feature is that it is a PEGylated Fab fragment without an Fc region, which limits active placental transfer during pregnancy. Tysabri binds alpha-4 integrin, blocking lymphocyte trafficking to both gut and brain tissue. The natalizumab vs certolizumab distinction shapes safety profile, administration, and the niche each drug occupies.

Crohn's Efficacy

Cimzia's Crohn's efficacy rests on PRECISE-1 and PRECISE-2, which showed significant clinical response and remission benefits over placebo. Tysabri's Crohn's efficacy rests on ENACT-1, ENACT-2, and ENCORE. No head-to-head trial has directly compared Tysabri with Cimzia in Crohn's. Indirect comparisons suggest similar efficacy in biologic-experienced Crohn's patients, with Cimzia offering the advantage of SC self-administration and Tysabri reserved for cases refractory to multiple mechanism classes.

PML Risk and TOUCH Program

Tysabri carries a black-box warning for PML. The TOUCH program requires enrollment, JC virus antibody testing, routine monitoring, and prescriber/pharmacy/infusion center certification. Most gastroenterologists reserve Tysabri for Crohn's patients who have failed multiple other biologic classes and who test negative for JC virus antibodies. Cimzia has no such restricted access program.

Cimzia Safety Profile

Cimzia carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. These risks are quantifiable and manageable with standard pre-treatment screening and ongoing monitoring, and they are substantially less severe than PML. For tysabri vs cimzia side effects, Cimzia is clearly preferred for patients with infection concerns or complex comorbidities.

Pregnancy Considerations

Cimzia's lack of an Fc region minimizes active placental transfer during pregnancy, resulting in very low infant drug levels at birth. Tysabri undergoes active placental transfer via FcRn like other IgG biologics. For Crohn's patients who are pregnant or planning pregnancy, Cimzia's pregnancy profile is often preferred over most other biologics.

Administration and Dosing

Cimzia for Crohn's uses 400 mg SC at weeks 0, 2, and 4 for induction, then 400 mg every 4 weeks for maintenance, per UCB's prescribing information. Cimzia is all-SC throughout and can be self-administered at home. Tysabri is administered as a 300 mg IV infusion every 4 weeks at a TOUCH-certified infusion center, per Biogen's prescribing information. Both drugs use an every-4-week cadence, but Cimzia's SC self-administration offers clear practical advantages over Tysabri's TOUCH-certified IV infusion.

Crohn's Niche Biologics

Both Cimzia and Tysabri occupy niche positions in Crohn's biologic therapy. Cimzia is often chosen for pregnancy considerations or patients who prefer SC therapy with a less frequent dosing schedule than Humira. Tysabri is reserved for refractory patients who have failed other biologic classes and test JC virus antibody negative. Neither drug is commonly prescribed as first-line Crohn's therapy.

When Tysabri Might Be Considered

For Crohn's patients who have failed multiple biologic classes (anti-TNFs like Cimzia or Humira, IL-12/23, gut-selective, IL-23 p19), Tysabri may be considered, particularly in patients who test negative for JC virus antibodies. This is a narrow population, and shared decision-making with a gastroenterologist experienced in refractory Crohn's is essential.

Anti-TNF Experienced Patients

For Crohn's patients who have already failed an anti-TNF like Humira or Remicade, cycling to Cimzia (another anti-TNF) is typically less effective than switching mechanism classes. Tysabri offers a different mechanism but comes with PML risk. Other options like Stelara, Entyvio, Skyrizi, Tremfya, or Omvoh are typically considered before either Cimzia (for anti-TNF experienced) or Tysabri.

Biosimilar Availability

Cimzia has no biosimilar currently on the US market. Tysabri has a biosimilar (Tyruko) approved in 2023, though real-world utilization in IBD remains low given TOUCH program requirements apply equally to biosimilars.

Choosing With Your GI

For a Crohn's patient deciding between Tysabri and Cimzia, Cimzia is preferred for most patients because of its favorable safety profile, SC self-administration, pregnancy considerations, and absence of TOUCH program restrictions. Tysabri is a niche option reserved for patients who have exhausted other biologic classes and who test JC virus antibody negative. If you are considering Tysabri, ask your GI about JC virus antibody status, prior treatment history, and the specific risk-benefit rationale. A log of stool frequency, urgency, abdominal pain, and any new neurological symptoms between visits is particularly important for patients on Tysabri.